TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00816426
Drug: Kanamycin
Normalized name: Kanamycin
DrugBank: Kanamycin (DB01172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
Study: NCT04622332
Drug: SIR1-365
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: oral
Study: NCT04622332
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: oral
Study: NCT04502251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The capsule presented the same format, size and color as LDN capsules, however the excipient used was starch.
Study: NCT02690155
Drug: VKA (Vitamin K antagonist)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by treating physicians
Study: NCT02963116
Drug: AZD5718 IR tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02963116
Drug: AZD5718 oral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02963116
Drug: Rosuvastatin tablet
Normalized name: Rosuvastatin Tablets
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03742180
Drug: sublingual ketorolac
Normalized name: ketorolac Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
Study: NCT02785250
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO BID
Study: NCT00823407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of placebo
Study: NCT01671800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04070742
Drug: FMX101
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03221751
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an inert oral capsule identical in appearance to prazosin capsules.
Study: NCT02969369
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT00801164
Drug: Frio Mouth Rinse Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
Study: NCT03986385
Drug: Apatinib Capecitabine Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
Study: NCT03986385
Drug: Capecitabine Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
Study: NCT04652323
Drug: Biocompatibility of calcium silicate cements
Normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The presence of inflammation, edema, necrosis, dystrophic calcification, and thickness of fibrous capsule formation was recorded by histological examination 7, 30, and 60 days after the implantation procedure of materials.
Study: NCT00807326
Drug: Probiotic Saccharomyces boulardii 250 mg capsules
Normalized name: Saccharomyces boulardii Chewable Tablet [Rezyst Probiotic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
Study: NCT05984251
Drug: CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05984251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03885258
Drug: Melatonin Replacement Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
Study: NCT00708149
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: takepron placebo
Study: NCT00006051
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00951847
Drug: oxcarbazepine 300 mg/5 mL oral suspension
Normalized name: Oxcarbazepine 300 MG/5 ML Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00528515
Drug: Diprivan (propofol), Astra-Zeneca
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous intravenous infusion with a dose of 3-5 mg/kg/h
Study: NCT00528515
Drug: Suprane (desflurane), Baxter
Approvals — FDA: no, EMA: no, PMDA: no
Description: a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
Study: NCT01722604
Drug: Azopt 1%
Normalized name: Azopt 1% Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azopt 1%, RLD
Study: NCT00648947
Drug: Plavix® Tablets 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg, single dose fasting
Study: NCT00467363
Drug: acetylsalicylic-acid (aspirin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81mg of low-dose aspirin plus 400micrograms of folic acid.
Study: NCT00043394
Drug: Herceptin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
Study: NCT00043394
Drug: 0.08 mg/kg CpG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
Study: NCT00043394
Drug: 0.16 mg/kg CpG 7909
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
Study: NCT03999684
Drug: Tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
Study: NCT04601792
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc. and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
Study: NCT04601792
Drug: Tested drug minus heat-clearing herbs
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is the decoction of the Syndrome Differentiation Decoction (tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria Baicalensis, Rhizoma Coptidisor Herba Violae will be removed from the Syndrome Differentiation Decoction.
Study: NCT04032119
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine
Study: NCT04152096
Drug: Rheosorbilact®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Study: NCT04152096
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study: NCT00780494
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 850mg/m2, Orally twice daily days 1-14 every 21 days.
Study: NCT05514860
Drug: Anti-Arrhythmic Drug Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
Study: NCT01382797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT00362765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00868374
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
Study: NCT02436447
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
Study: NCT02436447
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
Study: NCT02436447
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
Study: NCT03328676
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Study: NCT00652288
Drug: Insulin analogs (Lispro and Glargine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs given in single injection
Study: NCT00725803
Drug: GS-9450 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GS-9450 administered orally once daily
Study: NCT02453386
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00560443
Drug: ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,5 mg/kg per os one time
Study: NCT00927290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 45 mg QD (30 mg QD the first month)
Study: NCT02272647
Drug: IM Saline Placebo (0.25 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02272647
Drug: IM Estradiol valerate (2.5 mg)
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02272647
Drug: IM Saline Placebo (0.5 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00243386
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
Study: NCT00243386
Drug: Antihemophilic factor, recombinant, manufactured protein-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
Study: NCT02272647
Drug: IM Estradiol valerate (5.0 mg)
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02272647
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02272647
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (in lieu of Medroxyprogesterone)
Study: NCT01718496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with advanced COPD on the other study arm will randomly receive Placebo
Study: NCT02082392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A substance or treatment of no intended therapeutic value in a pill form.
Study: NCT04213105
Drug: QL1206
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of 60 mg (1ml) only once,on the first day.
Study: NCT01022242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a physiological sodium chloride solution, which is clear and colourless.
Study: NCT00545298
Drug: Nitric Oxide - same dose 6 wks
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
Study: NCT00545298
Drug: Nitric Oxide modified treatment
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
Study: NCT03218137
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
Study: NCT00004132
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01471171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
Study: NCT00525993
Drug: etoricoxib 90mg 14 days
Normalized name: etoricoxib 90 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: each patient in this group will receive 90mg once daily, for the 14 days treatment.
Study: NCT00525993
Drug: etoricoxib 60mg daily for 14 days
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group will receive 60mg of the drug, daily
Study: NCT01033825
Drug: AQ Nasal Spray Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQ Nasal Spray Placebo once daily
Study: NCT01550146
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv. Normal Saline 0.1 ml/kg
Study: NCT01328951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
Study: NCT01393054
Drug: Nigella sativa
Normalized name: NIGELLA SATIVA SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
Study: NCT01318434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00074321
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01093963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral; 20-70mg/day
Study: NCT02043548
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
Study: NCT00925054
Drug: rAvPAL-PEG 0.003 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, the planned starting dose levels is 0.003 mg/kg
Study: NCT00925054
Drug: rAvPAL-PEG 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, the planned starting dose levels is 0.03 mg/kg
Study: NCT00925054
Drug: rAvPAL-PEG 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, the planned starting dose levels is 0.1 mg/kg
Study: NCT02130739
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
Study: NCT01015651
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
Study: NCT01015651
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
Study: NCT01403818
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01403818
Drug: Mitiglinide calcium hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03985865
Drug: Intraduodenal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
Study: NCT00099047
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00099047
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00660426
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00665145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04355273
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study: NCT04355273
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study: NCT04355273
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study: NCT00394810
Drug: Panzem® NCD
Approvals — FDA: no, EMA: no, PMDA: no
Description: suspension, 100 mg/mL, four times daily continuous dosing
Study: NCT01473953
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
Study: NCT01802853
Drug: RO6811135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous dose
Study: NCT00254748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00150826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in a capsule form once daily for 16 weeks.
Study: NCT01392677
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
Study: NCT00966329
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART regimen including 2 NRTI/NtRTIs plus one of the following :~* 1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~* or ATV/unboosted (in a regimen without tenofovir)~* or 1 NNRTI (nevirapine or efavirenz).
Study: NCT03077685
Drug: NanoPac®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
Study: NCT01677754
Drug: RO4602522
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RO4602522 orally once daily for 12 months.
Study: NCT01613040
Drug: RO4917838
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily oral high doses of RO4917838 for 10 days
Study: NCT02785120
Drug: TF0023
Approvals — FDA: no, EMA: no, PMDA: no
Description: TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
Study: NCT02259881
Drug: Low dose of BIBT 986 CL, per i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259881
Drug: Medium dose of BIBT 986 CL, per i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259881
Drug: High dose of BIBT 986 CL, per i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02125227
Drug: Rosuvastatin, Metformin, YH14755
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT02125227
Drug: YH14755
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT03648658
Drug: Paracetamol 120Mg/5mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
Study: NCT03331445
Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
Normalized name: nitric oxide 0.5 % / nitrogen 99.5 % Gas for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide 160ppm balance air
Study: NCT01907334
Drug: Methacholine Chloride
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
Study: NCT00276848
Drug: Fludarabine plus Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
Study: NCT03707171
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
Study: NCT05729529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral gel used on tongue
Study: NCT03970694
Drug: oxaliplatin+capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.